A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

This study has been completed.
Sponsor:
Collaborator:
Tibotec Pharmaceutical Limited
Information provided by (Responsible Party):
Tibotec BVBA
ClinicalTrials.gov Identifier:
NCT00703118
First received: June 19, 2008
Last updated: December 5, 2013
Last verified: December 2013

June 19, 2008
December 5, 2013
October 2008
July 2010   (final data collection date for primary outcome measure)
Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
SVR24 planned is defined as having undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after the last planned dose of study medication.
Primary objective is to demonstrate the efficacy of telaprevir in combination with Peg-INF and RBV compared to Peg-INF and RBV in patients with chronic HCV, genotype 1, infection who failed prior treatment 24 weeks after last intake of study medication.
Complete list of historical versions of study NCT00703118 on ClinicalTrials.gov Archive Site
  • Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4 [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
    RVR was defined as having undetectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 4.
  • Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment) [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
  • Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned [ Time Frame: Week 60 ] [ Designated as safety issue: No ]
    SVR12 planned was defined as having undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) levels 12 weeks after the last planned dose of study medication (SVR12 planned).
  • Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8 [ Time Frame: Week 4, Week 6, or Week 8 ] [ Designated as safety issue: No ]
    Telaprevir stopping rule is defined as having Hepatitis C virus (HCV) ribonucleic acid (RNA) levels >100 IU/mL at Week 4, Week 6, or Week 8 after start of telaprevir.
  • Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72) [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    Viral relapse was defined as having confirmed detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) levels during entire follow-up period (up to Week 72).
  • Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 [ Time Frame: Baseline (Day 1) to Week 4 ] [ Designated as safety issue: No ]
  • Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12 [ Time Frame: Week 4 and Week 12 ] [ Designated as safety issue: No ]
    Extended rapid virologic response was defined as undetectable Hepatitis C virus (HCV) ribonucleic acid (RNA) levels.
The secondary objective is to evaluate the effect of a delayed start of telaprevir on efficacy.
Not Provided
Not Provided
 
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment

The purpose of this study is to determine the safety, efficacy and tolerability of using two regimens of telaprevir (with and without delayed start) with standard treatment compared to standard treatment alone in participants with chronic, genotype 1, hepatitis C.

This is a randomized, double-blind, placebo-controlled Phase III trial with telaprevir in patients with chronic Hepatitis C Virus (HCV), genotype 1, infection who failed prior treatment with standard treatment. Standard treatment is defined as treatment with Peg-INF and RBV. The trial is designed to compare the efficacy, safety, and tolerability of 2 regimens of telaprevir (with and without delayed start) combined with standard treatment versus standard treatment alone. The trial will consist of a screening period of approximately 4 weeks, a 48-week treatment period, and a 24-week follow-up period. Patients will be eligible to enroll in the trial if they (1) had an undetectable HCV Ribonucleic Acid (RNA) level at the end of a prior course of standard treatment but did not achieve a response (viral relapsers), or (2) never had an undetectable HCV RNA level during or at the end of a prior course of standard treatment (non-responders). Approximately 650 patients (350 prior relapsers and 300 prior non-responders) will be randomized in a 2:2:1 ratio to one of 3 treatment groups: Treatment group A will receive telaprevir with standard treatment for 12 weeks; followed by placebo with standard treatment for 4 weeks; followed by standard treatment for 32 weeks. Treatment group B will receive placebo with standard treatment for 4 weeks; followed by telaprevir with standard treatment for 12 weeks; followed by standard treatment for 32 weeks. Treatment group C will receive placebo with standard treatment for 16 weeks; followed by standard treatment for 32 weeks. In both telaprevir regimens (A and B), patients will receive 12 weeks of 750 mg of telaprevir every 8 hours along with 48 weeks of standard treatment. Telaprevir or placebo will be given by mouth at a dose of 750 mg every 8 hours for 16 weeks. Peg-INF will be given as an injection under the skin at a dose of 180 mcg once every week for 48 weeks. RBV will be given by mouth at a dose of either 1000 or 1200 mg (depending on your body weight) two times per day for 48 weeks.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hepatitis C, Chronic
  • Drug: Telaprevir
    Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
  • Drug: Peg-IFN-alfa-2a
    Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
  • Drug: Ribavirin
    Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
  • Drug: Placebo
    Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
  • Experimental: Group A: T12/PR48
    Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
    Interventions:
    • Drug: Telaprevir
    • Drug: Peg-IFN-alfa-2a
    • Drug: Ribavirin
    • Drug: Placebo
  • Experimental: Group B: T12(DS)/PR48
    Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
    Interventions:
    • Drug: Telaprevir
    • Drug: Peg-IFN-alfa-2a
    • Drug: Ribavirin
    • Drug: Placebo
  • Experimental: Group C: Pbo/PR48
    Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
    Interventions:
    • Drug: Peg-IFN-alfa-2a
    • Drug: Ribavirin
    • Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
663
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level >= 1000 IU/mL
  • Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard treatment)
  • Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication

Exclusion Criteria:

  • Patient is a previous non-responder that is classified as a viral breakthrough case
  • Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one subtype
  • Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other genotype
  • Evidence of decompensated liver disease
  • Patient has condition that requires use of systemic corticosteroids
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Austria,   Belgium,   Brazil,   Canada,   France,   Germany,   Israel,   Netherlands,   Poland,   Puerto Rico,   Spain,   Sweden,   Switzerland,   United Kingdom
 
NCT00703118
CR014842, VX-950-TIDP24-C216
Yes
Tibotec BVBA
Tibotec BVBA
Tibotec Pharmaceutical Limited
Study Director: Tibotec-Virco Virology BVBA Clinical Trial Tibotec BVBA
Tibotec BVBA
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP